Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics (NASDAQ: TVRD) will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Tvardi Therapeutics (NASDAQ: TVRD) will participate in one-on-one investor meetings at the Raymond James Biotech Innovation Symposium in New York City on April 14, 2026. Tvardi is a clinical-stage biopharmaceutical focused on oral small-molecule therapies targeting STAT3 for inflammatory and proliferative diseases.

Argus Apr 2 session

+0.67% close to close Open Argus

Details

News Market Reaction – TVRD

On Apr 2, the day this news came out, TVRD closed 0.67% above the previous close.

Data tracked by StockTitan Argus for the Apr 2 session.

Market Context

This announcement highlights Tvardi’s ongoing outreach to investors, with management set for one-on-...

Analysis

This announcement highlights Tvardi’s ongoing outreach to investors, with management set for one-on-one meetings at a biotech symposium on April 14, 2026. It comes after recent SEC filings detailing cash of $30.8 million, 2025 R&D of $18.0 million, and clinical timelines for TTI-101 and TTI-109. Historically, similar conference-participation updates produced modest price moves. Investors following the story may focus on upcoming clinical readouts and how capital resources support those milestones.

Key Figures

Resale registration: 2,084,117 shares Shares outstanding: 9,381,344 shares R&D expense: $5.5 million +5 more

Resale registration: 2,084,117 shares; Resale of common stock registered in 424B3 filings
Shares outstanding: 9,381,344 shares; Common stock outstanding as of March 26, 2026
R&D expense: $5.5 million; Q4 2025 research and development spending
R&D expense: $18.0 million; Full-year 2025 research and development spending
Net loss: $7.3 million; Q4 2025 net loss
Net loss: $18.2 million; Full-year 2025 net loss
Cash and investments: $30.8 million; Cash, cash equivalents and short-term investments at Dec 31, 2025
Passive stake: 426,190 shares (4.5%); Beneficial ownership reported in Schedule 13G/A

Historical Context

5 past events · Latest: Feb 12

5 events

Feb 12
Investor conferences

24h Move

-1.6%

Announced participation in four investor conferences during Feb–Mar 2026.
Jan 08
Conference presentation

24h Move

+7.6%

Planned J.P. Morgan presentation with new Phase 2 REVERT IPF data for TTI-101.
Jan 08
Clinical trial update

24h Move

+8.7%

Further Phase 2 REVERT IPF analyses for TTI-101 with mixed efficacy signals.
Nov 18
Conference participation

24h Move

+2.2%

Planned participation and fireside chat at Piper Sandler healthcare conference.
Nov 13
Earnings and update

24h Move

-1.9%

Q3 2025 results plus pipeline milestones and runway into Q4 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

stat3

1 terms

stat3 medical

"targeting STAT3 to treat inflammatory and proliferative diseases"

STAT3 is a protein inside cells that acts like a control knob for turning sets of genes on or off, influencing cell growth, survival and immune responses. For investors, STAT3 matters because drugs or tests that block or measure its activity can be used to treat or track cancers and inflammatory diseases, so progress on STAT3-targeted therapies or diagnostics can affect the value and prospects of biotech and pharmaceutical firms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

04/02/2026 - 08:00 AM

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in one-on-one investor meetings at the upcoming Raymond James Biotech Innovation Symposium in New York City, on April 14^th, 2026.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled, proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting clinical trials with TTI-101 in hepatocellular carcinoma (NCT05440708) and TTI-109 in healthy volunteers. To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Contacts:

For Tvardi:
Tvardi Investor Relations
ir@tvardi.com

PJ Kelleher
LifeSci Advisors
617-430-7579
pkelleher@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Tvardi (TVRD) meet investors at the Raymond James Biotech Innovation Symposium?

Tvardi management will hold one-on-one investor meetings on April 14, 2026 in New York City. According to Tvardi, these are one-on-one investor sessions at the Raymond James Biotech Innovation Symposium to discuss company developments and clinical-stage STAT3 programs.

What will Tvardi (TVRD) discuss at the April 14, 2026 investor meetings?

Tvardi is expected to discuss its clinical-stage programs targeting STAT3 for inflammatory and proliferative diseases. According to Tvardi, management will use one-on-one meetings to provide investor updates on program status, strategy, and potential next steps for development.

Is Tvardi (TVRD) presenting publicly or only in one-on-one meetings on April 14, 2026?

Tvardi's announcement specifies one-on-one investor meetings rather than a public presentation at the symposium. According to Tvardi, management will participate in private investor sessions during the Raymond James Biotech Innovation Symposium in New York City.

Where and when is the Raymond James Biotech Innovation Symposium that Tvardi (TVRD) will attend?

The symposium takes place in New York City, and Tvardi will meet with investors on April 14, 2026. According to Tvardi, management's participation consists of one-on-one investor meetings scheduled for that date at the event.

How can investors request a one-on-one meeting with Tvardi (TVRD) at the April 14, 2026 symposium?

The press notice states management will participate in one-on-one meetings but gives no contact details for scheduling. According to Tvardi, investors should use the company's investor relations channels to request meetings or additional participation information.

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium